DKDarko Kastelan

Darko Kastelan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Darko Kastelan has a total of 289 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Severity and management of hypercortisolism in patients with adrenocortical carcinoma and overt Cushing syndrome

    by Marta Araujo-Castro, Irina Bancos, Mario Detomas, Martin Reincke, Darko Kastelan, Melani Naglic, Anja Barac Nekic, Betina Biagetti, Anna Casteras Roman, Andrés Cardona, et al.

    Objective: To analyze the association between the degree of hypercortisolism and survival outcomes of patients with Cushing syndrome (CS) due to adrenocortical carcinoma (ACC). Methods: An international retrospective of patients with CS due to ACC. The primary outcomes were to evaluate the prognostic role of baseline hypercortisolism on survival outcomes, including progression-free survival, disease-free survival, and overall survival. Results: A total of 101 patients with ACC were included. The median urinary-free cortisol (UFC) levels at the time of CS diagnosis were 6.4 times above the upper limit of normal (ULN; IQR 2.9-14) and 53.5% (n = 54) of the cases had metastatic ACC. Maximum adrenal tumor size (odds ratio [OR] 1.02, 95% CI 1.01-1.03) and UFC levels (OR 1.62, 95% CI 1.03-2.57) were independent predictors of metastatic ACC. The median overall survival was 19.4 (range 1-176) months, the median disease-free survival was 12.3 (range 2.6-143) months, and progression-free survival was 5.6 (range 1.1-43.7) months. The risk of recurrence/progression increased as the severity of CS increased (21% in mild hypercortisolism [UFC 5×ULN], P = .035). UFC levels (hazard ratio 1.48; 95% CI 0.97-2.24, P = .057) tended to be associated with the risk of progression (metastatic ACC). When we considered a combined outcome (progression in metastatic ACC and recurrence in localized ACC), age, UFC, hypokalemia, R0 after surgery, and Ki-67 were independent predictors of recurrence/progression. Conclusion: Adrenal tumor size and the severity of cortisol excess are associated with a higher probability of metastatic disease at diagnosis. Our study suggests that the severity of cortisol excess appears to be associated with an increased risk of tumor recurrence/progression, suggesting that hypercortisolism intensity may serve as a marker of aggressive disease.

  • Open Access

    Does Automated Versus Manual Ki67 Labeling Index Assessment Influence Risk Stratification in Patients with Localized Adrenocortical Carcinoma? Lessons from the ADIUVO Trial

    by Marijn A. Vermeulen, Linde M. Amelung, Otilia Kimpel, Ulrich Dischinger, Vittoria Basile, Darko Kastelan, Hélène Lasolle, Isabelle Bourdeau, Svenja Nölting, Paola Loli, et al.

    Background/Objectives: Adrenocortical carcinoma (ACC) is a rare tumor. Diagnosis relies on combined histopathological criteria that, in a multifactorial scoring system, may suggest malignancy. The recent ADIUVO trial, a multicenter trial randomizing ACC patients between mitotane treatment or surveillance only, demonstrated that patients with localized, low-grade ACC (Ki67 labeling index (LI) ≤ 10%) have a better prognosis than historically anticipated, questioning the routine use of adjuvant mitotane. This post hoc analysis aimed to investigate whether automated, centralized Ki67 LI assessment improves prognostic stratification beyond expert manual assessment in low-risk ACC patients enrolled in the original ADIUVO trial. Methods: Ki67 LI was centrally reassessed in 70 ADIUVO patients by digitizing slides and applying an automated algorithm to manually selected hotspots. Primary endpoints were correlation between methods and the impact of automated scoring on recurrence-free survival (RFS) and overall survival (OS). Results: Automated Ki67 LI assessment was feasible in 47 patients. Manual and automated Ki67 LI values showed good agreement (mean 5.6 ± 3.1% vs. 5.4 ± 5.3%). Automated scoring identified eight patients with KI67 LI > 10%. In this subgroup, RFS and OS did not differ significantly between patients treated with mitotane and those under surveillance. Patients with an automated Ki67 LI > 10% had larger tumors (median 16.0 cm vs. 7.0 cm, p = 0.003). Conclusions: Our findings support the original ADIUVO results and support continued use of manual expert Ki67 LI scoring. This traditional approach remains robust and pragmatic for most clinical settings, especially where automated systems are not readily accessible.

  • Impact of postoperative hydrocortisone replacement dose on health-related quality of life and metabolic parameters in patients with cured Cushing’s syndrome: randomized, open-label, controlled trial

    by Anja Barac Nekic, Darko Kastelan, Mirsala Solak, Tanja Skoric Polovina, Annemarie Balasko, Ivana Kraljevic

    To evaluate the effect of postoperative hydrocortisone dosing on health-related quality of life (HRQoL), metabolic parameters, and hypothalamic-pituitary-adrenal (HPA) axis recovery in cured Cushing's syndrome (CS). This single-centre, randomized, open-label trial included 42 adults with CS and postoperative hypocortisolism randomised to hydrocortisone dose 15 mg/day or 30 mg/day during the first three postoperative months. HRQoL was assessed with e EQ-5D and SF-36 at baseline, at 1 and 3 months, and final follow-up while metabolic parameters were evaluated at baseline and 3 months. Dose effects on metabolic parameters were evaluated using ANCOVA; and HPA axis recovery was assessed using Kaplan-Meier and Cox regression analyses. No significant between-group differences in HRQoL were observed during the three-month period. EQ-5D visual analogue scale scores improved significantly at the final follow-up in both groups, while SF-36 domain scores showed overall improvement over time. At three months, patients receiving 15 mg/day had lower triglycerides, total cholesterol and, HbA1c levels; after adjustment for baseline values, hydrocortisone dose independently affected triglycerides and total cholesterol. No adrenal crises occurred, and there was no excess of acute intercurrent illness or hospitalization in the lower-dose group. HPA axis recovery occurred in 71% of patients and was not associated with hydrocortisone dose. In cured CS, 15 mg/day hydrocortisone does not worsen HRQoL and had better metabolic profile. HRQoL improves over time irrespective of dose suggesting no benefit from supraphysiological hydrocortisone replacement after curative surgery.

  • Open Access

    Clinical predictors of outcome in advanced adrenocortical carcinoma: a multicenter international ENSAT study

    by Alessandra Mangone, Barbara Altieri, Emanuele Ferrante, Irina Bancos, Michaela Luconi, Barbara Ziółkowska, Anja Barač Nekić, Rossella Libe, Filippo Ceccato, James F H Pittaway, et al.

    Objective: Advanced adrenocortical carcinoma (ACC) is treated with mitotane alone or combined with cytotoxic chemotherapy, yet outcomes remain poor and prognostic models in this setting are lacking. This study aimed to evaluate the prognostic value of clinical parameters in a large cohort of patients with advanced ACC undergoing systemic therapy. Methods: Multicenter, international cohort study investigating 418 patients with advanced ACC (61.5% = women, median age = 52 years) from 11 centers. Patients received mitotane monotherapy (n = 161), etoposide + doxorubicin + cisplatin ± mitotane (n = 178), or second-line regimens (gemcitabine + capecitabine ± mitotane or temozolomide + mitotane, n = 79). Variables included age, cortisol excess, performance status (ECOG-PS), tumor burden, and neutrophil-to-lymphocyte ratio (NLR) at start of therapy. Outcomes were overall survival (OS), time to progression (TTP), and best objective response. Results: Tumor burden, cortisol excess, ECOG-PS, and NLR ≥5 independently predicted shorter OS (hazard ratio [HR] 1.55-2.68). We developed an integrated ENSAT Risk Score for Advanced ACC combining these variables: tumor burden (0-2), cortisol excess (0/1), ECOG-PS (0-2), and NLR (0/1). A score >2 (poor-risk) was significantly associated with worse OS and TTP across all treatment groups (HRs for OS: 3.05-3.96; TTP: 2.53-3.08). It also predicted poorer response to mitotane (P < .01) and second-line therapies (P = .04). Conclusions: The ENSAT Risk Score for Advanced ACC is a practical, prognostic tool for patients with advanced ACC receiving systemic therapy. Based on accessible clinical and biochemical markers, it can support treatment decisions and facilitate informed discussions in routine care.


  • Open Access

    The Clinical Spectrum and Management of Ectopic Cushing’s Syndrome: A 12-Year Single-Center Experience

    by Ivana Kraljevic, Darko Kastelan, Gordan Vukman, Mirsala Solak, Tanja Skoric Polovina, Annemarie Balasko, Marija Tripolski, Anela Novak

    Ectopic Cushing’s syndrome is a severe endocrine disorder with high morbidity and mortality, making timely diagnosis and effective cortisol control crucial. The aim of this study was to assess the 12-year experience at a tertiary centre. We retrospectively analyzed clinical, biochemical, imaging, treatment, and outcome data in this single-center, non-interventional cohort of patients treated from 2012 to 2024 at the University Hospital Centre Zagreb. Twelve patients were included (10/12 female, 83.3%; median age 43.5 years, range 22–74). Primary tumors were predominantly neuroendocrine (8/12, 66.7%), and 9/12 (75.0%) had metastatic disease at diagnosis. Common features were fat redistribution in 10/12 (83.3%), facial plethora in 8/12 (66.7%), hypertension in 8/12 (66.7%), and peripheral edema in 7/12 (58.3%). Frequent biochemical alterations were hypokalemia in 11/12 (91.7%) and hyperglycemia or new-onset/worsening diabetes in 10/12 (83.3%). Median 24-hour urinary free cortisol was 5,594 nmol/24 h (range: 196–72,954), and ACTH 52.4 pmol/L (range: 8–498). A urinary free cortisol level≥50×the upper limit of normal identified a high-risk group with shorter survival (Spearman ρ=−0.50). Biochemical remission was achieved in 1/12 (8.3%) patient through tumor resection, while the majority required bilateral adrenalectomy (8/12, 66.7%) due to inadequate response to medical therapy or as first-line treatment. At the time of last follow-up, 8/12 (66.7%) patients had died due to disease progression, with a median time to death of 12 months (range: 1–51). The median overall survival was 20 months (range: 1–154). Most patients presented with metabolic disturbances and limited response to medical therapy, leading to bilateral adrenalectomy. Early mortality was driven by uncontrolled hypercortisolism rather than tumor burden, and higher urinary free cortisol was associated with shorter survival. These findings highlight the prognostic relevance of cortisol burden and the importance of prompt cortisol control.


  • Top Cited Papers
    Open Access

    Endocrine and metabolic determinants of cardiometabolic risk in mild autonomous cortisol secretion

    by Alessandro Prete, Lida Abdi, Marco Canducci, Elina L. van Den Brandhof, Ariadna Albors-Zumel, Carl Jenkinson, Lorna C. Gilligan, Yuanqing Zhang, Ludger Visser, Vasileios Chortis, et al.


  • Bone Health in Patients With Adrenal Adenomas and Hypercortisolism: A Multicenter Cross‐Sectional Study

    by Prerna Dogra, Lana Šambula, Jasmine Saini, Matthew T. Drake, Shobana Athimulam, Stylianos Tsagarakis, Dimitra A. Vassiliadi, Vasiliki Antonopoulou, Rohit Nathani, Catherine D. Zhang, et al.

    Objective: Data on bone health in patients with mild autonomous cortisol secretion (MACS) are limited and heterogenous. We sought to assess the prevalence of osteoporosis and symptomatic fragility fractures in patients with adrenal adenomas and hypercortisolism, and explore associations with the degree of cortisol excess and frailty. Design: This multicenter cross ‐sectional study involved prospective enrollment of adults with nonfunctioning adrenal adenomas (NFA), MACS, Cushing syndrome (CS) and referent subjects without adrenal disorders during the study period (January 2019–September 2022). All participants completed a bone health questionnaire at enrollment and had dual‐energy X ‐ray absorptiometry bone mineral density assessment within 12‐months. Final analyses were adjusted for age, sex, body mass index, smoking status, alcohol use. Results: Participants included 117 with NFA (median age 62 years, 80% women), 191 with MACS (median age 63 years, 74% women), 62 with CS (median age 50 years, 92% women), and 101 referent subjects (median age 59 years, 47% women). Both patients with CS (OR: 3.0, 95% CI: 1.1–8.3) and MACS (OR: 2.2, 95% CI: 1.9–4.9) had a higher prevalence of osteoporosis when compared to referents. Among patients with MACS, only those with post 1‐mg dexamethasone suppression test (post‐1mg‐DST) cortisol > 83 nmol/L had a higher prevalence of osteoporosis when compared to referents (OR: 3.2, 95% CI: 1.4–7.5) and NFA (OR: 2.2, 95% CI: 1.1–4.4). For clinical fragility fractures, only patients with CS showed an increased prevalence when compared to referents (OR: 6.1, 95% CI: 1.7–26.4) and NFA (OR: 3.8, 95% CI: 1.3–11.2). Prevalence of clinical fragility fractures was similar to referents in patients with MACS (OR: 1.8, 95% CI: 0.6–6.9) and NFA (OR: 1.5, 95% CI: 0.4–6.1), and was not associated with post‐1mg‐DST cortisol or frailty in the MACS and NFA groups. Conclusion: Patients with CS, and those with MACS and post‐1mg‐DST cortisol > 83 nmol/L, exhibited a higher burden of osteoporosis. However, only CS was associated with an elevated risk of symptomatic fragility fractures.


  • Bone Health in Patients With Adrenal Adenomas and Hypercortisolism: A Multicenter Cross‐Sectional Study

    by Prerna Dogra, Lana Šambula, Jasmine Saini, Matthew T. Drake, Shobana Athimulam, Stylianos Tsagarakis, Dimitra A. Vassiliadi, Vasiliki Antonopoulou, Rohit Nathani, Catherine D. Zhang, et al.

    Objective: Data on bone health in patients with mild autonomous cortisol secretion (MACS) are limited and heterogenous. We sought to assess the prevalence of osteoporosis and symptomatic fragility fractures in patients with adrenal adenomas and hypercortisolism, and explore associations with the degree of cortisol excess and frailty.Design: This multicenter cross ‐sectional study involved prospective enrollment of adults with nonfunctioning adrenal adenomas (NFA), MACS, Cushing syndrome (CS) and referent subjects without adrenal disorders during the study period (January 2019–September 2022). All participants completed a bone health questionnaire at enrollment and had dual‐energy X‐ray absorptiometry bone mineral density assessment within 12‐months. Final analyses were adjusted for age, sex, body mass index, smoking status, alcohol use.Results: Participants included 117 with NFA (median age 62 years, 80% women), 191 with MACS (median age 63 years, 74% women), 62 with CS (median age 50 years, 92% women), and 101 referent subjects (median age 59 years, 47% women). Both patients with CS (OR: 3.0, 95% CI: 1.1–8.3) and MACS (OR: 2.2, 95% CI: 1.9–4.9) had a higher prevalence of osteoporosis when compared to referents. Among patients with MACS, only those with post 1‐mg dexamethasone suppression test (post‐1mg‐DST) cortisol > 83 nmol/L had a higher prevalence of osteoporosis when compared to referents (OR: 3.2, 95% CI: 1.4–7.5) and NFA (OR: 2.2, 95% CI: 1.1–4.4). For clinical fragility fractures, only patients with CS showed an increased prevalence when compared to referents (OR: 6.1, 95% CI: 1.7–26.4) and NFA (OR: 3.8, 95% CI: 1.3–11.2). Prevalence of clinical fragility fractures was similar to referents in patients with MACS (OR: 1.8, 95% CI: 0.6–6.9) and NFA (OR: 1.5, 95% CI: 0.4–6.1), and was not associated with post‐1mg‐DST cortisol or frailty in the MACS and NFA groups.Conclusion: Patients with CS, and those with MACS and post‐1mg‐DST cortisol > 83 nmol/L, exhibited a higher burden of osteoporosis. However, only CS was associated with an elevated risk of symptomatic fragility fractures.

  • Do adrenal incidentalomas have an impact on mental health? A comprehensive review

    by Darko Kastelan, Tina Dusek

    Adrenal incidentalomas (AIs) are increasingly detected during imaging performed for conditions unrelated to adrenal pathology. Numerous studies have shown that the presence of AI is associated with a higher frequency of hypertension, type 2 diabetes, dyslipidemia, obesity, and osteoporosis. This increased morbidity is mostly related to mild autonomous cortisol secretion, which is the most common hormonal abnormality in these patients. It is well known that glucocorticoid excess affects the hippocampus and prefrontal cortex, brain structures involved in mood regulation and cognitive processes, leading to a wide range of psychiatric symptoms, including depression. While these effects are well documented in patients with Cushing's syndrome, data on mental health changes in patients with AIs remain scarce. Additionally, the few existing studies have several limitations, leaving important clinical questions unanswered. Consequently, the extent to which AIs are associated with impaired mental health and whether patients would benefit from surgical treatment remains unclear. Addressing these challenges is crucial for developing adequate management strategies. This review explores potential psychological and psychiatric implications of AIs. By synthesizing existing literature, we aim to explain the relationship between AIs and mental health disorders, providing a background for future research and clinical practice guidelines.


  • Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

    by Ivana Dora Vodanović, Anja Barač Nekić, Lana Šambula, Karin Zibar Tomšić, Tina Dušek, Darko Kaštelan

    Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events. A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane. Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events. Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.